Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/20
Earnings Preview: Homology Medicines (FIXX) Q2 Earnings Expected to DeclineZacks Investment Research • 08/06/20
Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU ProgramGlobeNewsWire • 05/26/20
Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual MeetingGlobeNewsWire • 05/12/20
Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease ModelGlobeNewsWire • 03/16/20
Homology Medicines' Gene Therapy For Phenylketonuria Found Safe, Efficacy Data MixedBenzinga • 12/18/19
Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKUGlobeNewsWire • 12/17/19
Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPsGlobeNewsWire • 11/26/19
Earnings Preview: Homology Medicines (FIXX) Q3 Earnings Expected to DeclineZacks Investment Research • 11/05/19
Homology Medicines Presents Preclinical Data From Its Investigational PKU Gene Editing Program, Demonstrating Phenotypic Correction and Molecular Confirmation of Editing PrecisionGlobeNewsWire • 10/25/19
Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time TherapiesGlobeNewsWire • 10/21/19
Homology Medicines (FIXX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 05/06/19
